# Combining Latency Reversing Agents to Address the HIV Reservoir

> **NCT07384624** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- HIV (Human Immunodeficiency Virus)
- HIV -1 Infection

## Interventions

- **DRUG:** Pyrimethamine (PYR)
- **DRUG:** Lenalidomide
- **DRUG:** Topiramate (drug)

## Key facts

- **NCT ID:** NCT07384624
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-06
- **Final completion:** 2028-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07384624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07384624, "Combining Latency Reversing Agents to Address the HIV Reservoir". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07384624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*